XENO-AUTOANTIBODIES

Immune Recognition of Xeno-Glycans

Coordinatore	TEL AVIV UNIVERSITY    more  Organization address address: RAMAT AVIV city: TEL AVIV postcode: 69978 contact info Titolo: Ms. Nome: Lea Cognome: Pais Email: send email Telefono: 97236408774 Fax: 97236409697
Nazionalità Coordinatore	Israel [IL]
Totale costo	227˙231 €
EC contributo	227˙231 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-IIF
Funding Scheme	MC-IIF
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-03-01   -   2015-02-28

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	TEL AVIV UNIVERSITY  Organization address address: RAMAT AVIV city: TEL AVIV postcode: 69978 contact info Titolo: Ms. Nome: Lea Cognome: Pais Email: send email Telefono: 97236408774 Fax: 97236409697	IL (TEL AVIV)	coordinator	227˙231.20

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'‘xeno-autoantibodies’ recognize a dietary immunogenic non-self sugar that is metabolized by cells as self and presented on the cell surface. N-acetylneuraminic acid (Neu5Ac) and its hydroxylated form, N-glycolylneuraminic acid (Neu5Gc) are the two major Sia forms in most mammals. Humans are deficient in the enzyme CMP-Neu5Ac hydroxylase (CMAH) that can synthesize Neu5Gc, however dietary Neu5Gc accumulates in epithelial tumors and become immunogenic. Our previous research recognized dual and opposing roles of IgG isotype xeno-autoantibodies in cancer progression, diagnosis and immunotherapy: they facilitate tumor progression via chronic inflammation at low doses, but mediate tumor inhibition at higher doses in a ‘human-like’ Cmah-/- Neu5Gc-deficient mouse model. Furthermore, we developed a novel sialoglycan microarray that lead to the discovery of a specific xeno-auto-IgG that is novel human serum carcinoma biomarker and potential immunotherapeutic. However, our early studies also revealed that some human sera show high levels of anti-Neu5Gc IgAs that could even be affinity-purified from human serum (7). IgA is the most abundantly produced antibody isotype in the body and the main isotype in mucosal surfaces; It is also present in serum, where IgG is the predominant isotype. I propose a multidisciplinary approach to investigate the biology of IgA xeno-autoantibodies against these unique glycans and their potential involvement in cancer. I will combine glycobiology, immunology, biochemistry, molecular biology, nanotechnology and advanced array techniques to address these lines of investigation both in vitro and in vivo in a relevant mouse model (Cmah-/-).'